Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Healthcare Biotechnology

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by lv_426on Nov 20, 2019 2:46pm

45 Views

Post# 30375088

RE:RE:RE:Insider buying 0,40$ each share!

Ingiboy wrote: I am sure Mr. Shutte is not thrilled to see the share price at $.155 today after paying $.40 for Preferred Class A shares last September.
Mr Shutte was first a major shareholder for a number of years before becomming a Director of Replicel last year.

I agree this is a substantial committment on his part at this critical time.

You realize that when replicel liquidates, prefered shares get priority over common shares

Bullboard Posts

Futures Flat Amid Key Data in Canada and US